Exelixis, Inc. 10-Q Summary: Quarter Ended March 31, 2000
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2000, for Exelixis, Inc., a model system genetics and comparative genomics company. The firm operates in a single segment within the United States, focusing on identifying critical genes in disease pathways for pharmaceutical and agricultural applications. As of April 30, 2000, there were 42,765,662 shares of common stock outstanding. The company completed its Initial Public Offering (IPO) on April 14, 2000, shortly after the reporting period.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Total Revenues | $5.95 million | $1.20 million |
| Net Loss | ($7.29 million) | ($3.57 million) |
| Net Loss Per Share (Basic/Diluted) | ($1.23) | ($1.28) |
| Cash and Cash Equivalents (End of Period) | $12.00 million | $13.73 million |
| Total Cash, Equivalents & Short-Term Investments | $13.50 million | Filing text does not provide a clear combined value for 1999 |
| Net Cash Provided by Operating Activities | $10.21 million | $1.04 million |
| Net Cash Used in Investing Activities | ($3.60 million) | ($5.43 million) |
| Accumulated Deficit | ($62.01 million) | Filing text does not provide a clear value for 1999 |
| Total Liabilities | $35.72 million | $21.73 million |
Revenue Breakdown (Q1 2000): License revenues were $0.93 million; Contract revenues were $5.02 million.
Expense Breakdown (Q1 2000): Research and Development (R&D) expenses were $8.93 million (including $2.00 million stock compensation); General and Administrative (G&A) expenses were $4.30 million (including $1.26 million stock compensation).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 397% year-over-year, driven by additional license and contract revenues from collaborations with Bayer, Pharmacia, and Bristol-Myers Squibb.
- Expense Expansion: R&D expenses rose 170% and G&A expenses rose 200%. Increases were attributed to higher staffing costs, facility expansion, and significant non-cash stock compensation expenses ($3.26 million recognized in Q1 2000 vs. $0.32 million in Q1 1999).
- Liquidity Position: Despite a net loss of $7.29 million, the company generated $10.21 million in operating cash flow, primarily due to a $13.48 million increase in deferred revenue from collaborators. Cash and cash equivalents increased from $5.40 million to $12.00 million during the quarter.
- Balance Sheet: Total assets grew from $18.90 million to $29.40 million, while total liabilities increased from $21.73 million to $35.72 million, largely due to deferred revenue and lease obligations.
Outlook, Risks, and Unusual Items
- Capital Resources: Management expects current cash, short-term investments, and collaborator funding, combined with IPO proceeds (approx. $108.6 million net), to satisfy cash needs for at least two years. However, additional financing may be required.
- Future Losses: The company anticipates continuing to incur net losses and negative cash flow as it expands R&D and administrative infrastructure.
- Key Risks:
- Collaboration Dependency: Substantially all revenues are derived from collaborations with Bayer, Pharmacia, and Bristol-Myers Squibb. Termination or failure to meet milestones in these agreements would severely impact revenue.
- Technology and Commercialization: The company relies on unproven technologies and has no experience in product manufacturing or marketing.
- Regulatory and Social: Products may face lengthy regulatory approval processes and public resistance to genetically engineered products.
- Intellectual Property: Success depends on obtaining and defending patents; third-party infringement claims could be costly.
- Unusual Items: The company entered into a lease amendment for an additional 49,000 square feet of space with future payments totaling approximately $32 million. Warrants valued at $518,000 were issued in connection with this lease.
Investor Verification Checklist
- Verify the status and milestone achievement of the three major collaboration agreements (Bayer, Pharmacia, Bristol-Myers Squibb) to assess revenue sustainability.
- Confirm the utilization of IPO proceeds and the timeline for the new 49,000 sq. ft. facility lease payments beginning in Q2 2001.
- Review the vesting schedules and fair value assumptions for the significant stock compensation expenses ($3.3 million in Q1 2000).
- Assess the company's ability to raise additional capital if the two-year runway estimate proves insufficient due to accelerated spending.
- Monitor the conversion of mandatorily redeemable convertible preferred stock and the impact of the 4-for-3 reverse stock split on share count and liquidity.